ALXN Alexion Pharmaceuticals Inc.

128.8
+1.57  (+1%)
Previous Close 127.23
Open 128
Price To Book 2.98
Market Cap 28881753163
Shares 224,237,214
Volume 1,127,965
Short Ratio
Av. Daily Volume 1,313,065

NewsSee all news

  1. Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
  2. 3 Reasons Growth Investors Will Love Alexion (ALXN)
  3. Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
  4. ALXN or ALKS: Which Is the Better Value Stock Right Now?
  5. Alexion to Present at the RBC Capital Markets Annual Healthcare Conference

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b/3 trial to be initiated early 2020.
CAEL‐101
AL amyloidosis
PDUFA date under priority review June 28, 2019.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
NDA filing submitted April 2019.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
FDA approval announced December 21, 2018.
ULTOMIRIS (ravulizumab-cwvz)
Paroxysmal nocturnal hemoglobinuria (PNH)
Approval announced October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)
Phase 3 enrolment to be completed early 2020.
ALXN1840 (WTX101)
Wilson disease
Phase 3 trial initiated 1Q 2019.
ULTOMIRIS (ravulizumab-cwvz)
Generalized myasthenia gravis (gMG)
Phase 1b/2a trial to be completed in 2019.
ALXN1830
Warm autoimmune hemolytic anemia (WAIHA)
Phase 3 PK data due early 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)

Latest News

  1. Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
  2. 3 Reasons Growth Investors Will Love Alexion (ALXN)
  3. Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
  4. ALXN or ALKS: Which Is the Better Value Stock Right Now?
  5. Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
  6. Alexion to Present at the UBS Global Healthcare Conference
  7. Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
  8. Alexion Pharmaceuticals, Inc. (ALXN): Sound Shore Says the Pharmaceutical Company is Driving Innovation
  9. What Makes Alexion (ALXN) a New Buy Stock
  10. Biotech ETFs in Focus on String of Q1 Earnings Beats
  11. See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
  12. New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
  13. Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
  14. The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
  15. Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
  16. Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "
  17. Top Biotech Stocks for February 2019
  18. Edited Transcript of ALXN earnings conference call or presentation 25-Apr-19 12:00pm GMT
  19. Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)